HSP27 and Anti-HSP27 Antibodies Modulate PCSK9 Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for lowering LDL cholesterol levels, such as inhibiting the LDL receptor-PCSK9 interaction, are challenging due to the large size and extensive intermolecular contacts of these proteins, and existing drugs like HMG-CoA reductase inhibitors suffer from side effects like liver toxicity and up-regulation of PCSK9.
Innovation Solution
The use of heat shock protein 27 (HSP27) and anti-HSP27 antibodies to reduce the expression of PCSK9 in mammalian subjects, either alone or in combination with adjuvants, to enhance the efficacy of PCSK9 reduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies or small molecule inhibitors are used to block LDL receptor-PCSK9 interaction, then PCSK9 activity can be inhibited, but the large size and extensive intermolecular contacts of these proteins make successful blocking particularly difficult and challenging
Solution Approach 1:
The patent extracts and targets specific critical regions or epitopes on the PCSK9 protein surface that are essential for LDL receptor binding. By identifying and blocking these key interaction sites rather than attempting to block the entire large protein interface, the invention overcomes the difficulty posed by the extensive intermolecular contacts of the large proteins.
2Quantity of substance
If HMG-CoA reductase inhibitors are administered to lower LDL cholesterol levels, then hepatic LDL receptor expression is increased to enhance LDL uptake, but these drugs cause liver toxicity and up-regulate PCSK9 expression
Solution Approach 1:
The patent converts the harmful up-regulation of PCSK9 caused by conventional statin therapy into a beneficial target for intervention. By developing antibodies or inhibitors that specifically target PCSK9, the invention addresses the compensatory mechanism that limits statin efficacy, thereby converting the drug-induced harmful effect into a new therapeutic opportunity.
Solution Approach 2:
The invention introduces PCSK9-specific antibodies or inhibitors as intermediary molecules that block the interaction between PCSK9 and the LDL receptor. This intermediary approach allows for selective inhibition of PCSK9 function without requiring direct modification of the LDL receptor itself, enabling precise control over the therapeutic mechanism.
3Reliability
If the LDL receptor-PCSK9 interaction is blocked to treat cholesterol disorders, then PCSK9-mediated degradation of LDL receptors is reduced, but the large molecular weight and extensive contact area of these proteins make effective blocking particularly difficult
Solution Approach 1:
The patent applies local quality by targeting specific critical epitopes or binding sites on the PCSK9 protein surface rather than attempting to block the entire extensive interface. By focusing inhibition on key local regions that are essential for LDL receptor binding, the invention achieves effective blocking despite the large overall contact area of the protein-protein interaction.
Data Source
AI summary
This disclosure pertains to compositions and methods for reducing serum cholesterol in mammalian subjects. The exemplary compositions comprise mixtures of HSP27 protein or fragments thereof, a HSP25 protein or fraction thereof, a recombinant rHSP25 peptide, or a recombinant HSP27 peptide in a mixture with an adjuvant. The compositions may optionally comprise anti-HSP27 antibody. The methods for reducing serum cholesterol in mammalian subjects relate to the use of the compositions to increase the subjects' levels of serum HSP27 and/or anti-HSP27 antibodies.